About Ureteral Stents
A ureteric stent (also called a J-J stent or double-J stent) is a thin, flexible plastic tube which is curled at both ends to avoid damaging the kidney and urinary bladder and to prevent it from dislocating. The stent is placed so that its upper end is in the kidney and its lower end is in the urinary bladder. The stent is often used when there is a blockage in the ureter (for example, from a kidney stone) and allows urine to drain around the blockage. Ureteral stenting and help restore urine flow through blocked ureters and return the kidney to normal function.
Attributes | Details |
---|
Study Period | 2018-2030 |
Base Year | 2023 |
Unit | Value (USD Million) |
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Ureteral Stents market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.
B. Braun Melsungen AG (Germany), Bard Medical (United States), Coloplast (Denmark), Boston Scientific (United States), Applied Medical (United States), Allium Medical (Israel), Amecath (Egypt), Gohar Shafa Co (Iran), Olympus (Japan) and ProSurg (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Medi-Globe Group (Switzerland), Teleflex Incorporated (United States) and Others.
Segmentation Overview
AMA Research has segmented the market of Global Ureteral Stents market by , Application (Kidney Stone, Stricture (Abnormal Narrowing of the Ureter) and Tumour causing a blockage) and Region.
On the basis of geography, the market of Ureteral Stents has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Size, the sub-segment i.e. <10cm will boost the Ureteral Stents market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Material, the sub-segment i.e. Nitinol (Nickel/Titanium Alloy) will boost the Ureteral Stents market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Hospitals will boost the Ureteral Stents market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
Influencing Trend:
Growing Patient Awareness Regarding Advanced Medical Devices and The Increasing Healthcare Spending By Emerging Economies
Market Growth Drivers:
Increasing Prevalence and Recurrence Rate Of Kidney Stones Globally, High Percentage of Recurrence of Blockage Due to Tumour and Rising Awareness Regarding Overall Kidney Health
Challenges:
Lack of Treatment Awareness in Certain Countries and Availability of Alternative Treatments for Kidney Problems
Restraints:
Unfavourable Healthcare Reforms in some countries
Opportunities:
Improving Health Care Infrastructure, Advancements in Ureteral Stents Technique and Favourable Reimbursement Policies
Market Leaders and their expansionary development strategies
In September 2021, B. Braun Melsungen AG announces that it has acquired the minority interest of the cofounders Jean-Philippe Gentes and Bertrand Bolduc in Sterinova Inc. and now owns 100% of the company. Sterinova will continue to operate as a distinct subsidiary of B. Braun Melsungen AG.
In October 2020, Allium Medical Solutions Ltd., which specializes in minimally invasive technologies providing to large markets innovative solutions for clinical needs that are not adequately addressed, announced today that its urological stents received CE Mark for a new indication for treating urethral fistula after a successful trial.
The new regulation presents 22 rules, 4 more than the previous directive, and its demands have obliged the reclassification or even up the classification of products. In order to determine the proper classification of the urinary stents, the classification rules of Annex VIII of Medical Device Regulation (MDR) have to be considered, as well as other criteria such as the duration of contact with the patient, the degree of invasiveness and the parts of the body affected by the use of the device. As urinary stents are invasive devices that will be inserted into the body through the urethra, they could be considered either Class IIa (if used for more than 2 h but up to 30 days) or Class IIb (if used for more than 30 days), according to Rule 5 of MDR.
Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Manufactures of Ureteral Stents, Suppliers and Distributors of Ureteral Stents, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industry
About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.
Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.
The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.